ESTRELLA IMMUNOPHARMA, INC. Other General and Administrative Expense
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Other General and Administrative Expense of $45.90 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherGeneralAndAdministrativeExpense · last filed 2026-08-13
- ESTRELLA IMMUNOPHARMA, INC. other general and administrative expense for the quarter ending 2026-06-30 was $45.90K, a 2.53% increase year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. other general and administrative expense for the quarter ending 2026-03-31 was $149.11K, a 202.19% increase year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. other general and administrative expense for the quarter ending 2025-12-31 was $29.07K, a 29.55% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. other general and administrative expense for the quarter ending 2025-09-30 was $102.97K, a 198.14% increase year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. other general and administrative expense for fiscal 2025 was $226.14K.
| Period end | Other General and Administrative Expense 3 month | Other General and Administrative Expense 6 month | Other General and Administrative Expense 9 month | Other General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $45.90K 10-Q · filed 2026-08-13 | $86.38K 10-Q · filed 2026-08-13 | $224.07K derived: sum of 3 quarters · filed 2026-08-13 | $327.04K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $149.11K 10-Q · filed 2026-05-18 | $178.18K derived: sum of 2 quarters · filed 2026-05-18 | $281.14K derived: sum of 3 quarters · filed 2026-05-18 | $325.91K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $29.07K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $132.03K derived: sum of 2 quarters · filed 2026-03-18 | $176.79K derived: sum of 3 quarters · filed 2026-08-13 | $226.14K 10-K · filed 2026-03-18 |
| 2025-09-30 | $102.97K 10-Q · filed 2025-11-12 | $147.73K derived: sum of 2 quarters · filed 2026-08-13 | $197.07K 10-Q · filed 2025-11-12 | $238.33K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $44.76K 10-Q · filed 2026-08-13 | $94.11K 10-Q · filed 2026-08-13 | $135.36K derived: sum of 3 quarters · filed 2026-08-13 | $169.90K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $49.34K 10-Q · filed 2026-05-18 | $90.60K derived: sum of 2 quarters · filed 2026-05-18 | $125.14K derived: sum of 3 quarters · filed 2026-05-18 | $178.88K derived: sum of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | $41.26K derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-18 | $75.79K 10-K · filed 2026-03-18 | $129.54K derived: sum of 3 quarters · filed 2026-03-18 | $166.93K derived: sum of 4 quarters · filed 2026-03-18 |
| 2024-09-30 | $34.54K 10-Q · filed 2025-11-12 | $88.28K derived: sum of 2 quarters · filed 2025-11-12 | $125.67K 10-Q · filed 2025-11-12 | $125.67K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $53.74K 10-Q · filed 2025-08-12 | $91.14K 10-Q · filed 2025-08-12 | $91.14K derived: sum of 3 quarters · filed 2025-08-12 | $831.82K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $37.40K 10-Q · filed 2025-05-14 | $37.40K derived: sum of 2 quarters · filed 2025-05-14 | $740.68K 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | $740.68K 10-Q · filed 2024-02-14 | ||
| 2023-09-30 | $740.68K 10-Q · filed 2023-11-20 | |||
| 2023-03-31 | $63.49K 10-Q · filed 2024-05-15 | $126.97K derived: sum of 2 quarters · filed 2024-05-15 | $190.46K 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $63.49K 10-Q · filed 2024-02-14 | $126.97K 10-Q · filed 2024-02-14 | ||
| 2022-09-30 | $63.49K 10-Q · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |